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High-performance liquid chromatography and derivative 
spectrophotometry for simultaneous determination of 
pravastatin and fenofibrate in the dosage form
High performance liquid chromatography (HPLC) and 
second-order derivative spectrophotometry have been 
used for simultaneous determination of pravastatin (PS) 
and fenofibrate (FF) in pharmaceutical formulations. HPLC 
separation was performed on a phenyl HYPERSIL C18 col-
umn (125 mm × 4.6 mm i.d., 5 μm particle diameter) in the 
isocratic mode using a mobile phase acetonitrile/0.1 % di-
ethyl amine (50:50, V/V, pH 4.5) pumped at a flow rate of 1.0 
mL min–1. Measurement was made at 240 nm. Both drugs 
were well resolved on the stationary phase, with retention 
times of 2.15 and 5.79 min for PS and FF, respectively. Cali-
bration curves were linear (R = 0.999 for PS and 0.996 for FF) 
in the concentration range of 5–50 and 20–200 μg mL–1 for 
PS and FF, respectively.
Pravastatin and fenofibrate were quantitated in combined 
preparations also using the second-order derivative re-
sponse at 237.6 and 295.1 nm for PS and FF, respectively. 
Calibration curves were linear, with the correlation coeffi-
cient R = 0.999 for pravastatin and fenofibrate, in the con-
centration range of 5–20 and 3–20 μg mL–1 for PS and FF, 
respectively. Both methods were fully validated and com-
pared, the results confirmed that they were highly suitable 
for their intended purpose.
Keywords: pravastatin, fenofibrate, spectrophotometry, 
HPLC, dosage form
Pravastatin is a member of the drug class of statins, used in combination with diet, 
exercise, and weight-loss for lowering cholesterol and preventing cardiovascular diseases 
(1). Its chemical structure is: (3R,5R)-3,5-dihydroxy-7-((1R,2S,6S,8R,8aR)-6-hydroxy-2-meth-
yl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)-heptanoic acid 
(Fig. 1).
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a combination dosage form of pravastatin and fenofibrate (Pravafenix capsule) is in-
dicated for the treatment of high coronary heart disease-risk adult patients with mixed 
dyslipidaemia characterized by high TG and high LDL levels, whose LDL levels are ade-
quately controlled while on a treatment with pravastatin 40 mg monotherapy (2).
Various methods cited in the literature for determination of pravastatin involved high 
performance liquid chromatography HPLC-UV (3–5), HPLC-mass spectrometry (HPLC-
MS) (6–9) and voltammetry (10). Fenofibrate is official in USP (11) and BP (12) but different 
methods have been cited in the literature for determination of fenofibrate involving HPLC-
UV (13, 14) and HPLC-MS (15), voltammetry (16) and differential pulse polarographic tech-
niques (17). A stability indicating UPLC method for simultaneous determination of ator-
vastatin, fenofibrate and their impurities in tablets was developed and validated (14). 
Chromatographic separation was performed on the reversed phase stationary phase using 
gradient elution. no HPLC or spectrophotometric method has been reported in the litera-
ture for simultaneous determination of pravastatin and fenofibrate in their commercial 
formulations. However, a HPLC and second-derivative spectrophotometry have been ap-
plied to analysis of atorvastatin and fenofibrate in combined tablets (18, 19). Therefore, the 
present work describes two analytical procedures for the quantitation of pravastatin and 
fenofibrate in their single dosage form using reversed phase HPLC and second-derivative 
spectrophotometry.
Fig. 1. Chemical structures of: a) pravastatin, b) fenofibrate and c) darifenacin (IS).
Fenofibrate is mainly used to reduce cholesterol levels in patients at risk of cardiovas-
cular diseases. Like other fibrates, it reduces the levels of both low-density lipoprotein 
(LDL) and very low density lipoprotein (VLDL) increases high-density lipoprotein (HDL) 
and reduces triglyceride (TG) levels. It is used alone or in conjunction with statins in the 
treatment of hypercholesterolemia and hypertriglyceridemia. Its chemical name is: propan-
2-yl-2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate (Fig. 1).
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Pravastatin (> 99 % purity) and fenofibrate (> 99 % purity) were obtained from Sigma 
Co. (Germany). Darifenacin hydrobromide (> 99 % purity) to be used as IS was purchased 
from novartis International Pharmaceutical Ltd. (Ireland). Structures of the standards are 
given in Fig. 1. HPLC-grade acetonitrile and analytical grade diethyl amine and ortho-phos-
phoric acid were purchased from BdH Chemicals (UK). Bidistilled water was purified us-
ing a cartridge system and ultra pure water of 5.56 × 10–8 S was obtained from a Milli-Q plus 
purification system, Millipore (waters, USa).
Apparatus
The HPLC analysis was carried out on a waters HPLC system (USa) equipped with 
a 1500 series HPLC pump, operating at a flow rate of 1.0 mL min–1. A dual wavelength UV-
Visible detector (2475) and an autosampler (717 plus) were used. Data was collected with 
an Empower pro Chromatography Manager for data acquisition and analysis. Chromato-
graphic separations were performed with an analytical column phenyl HYPERSIL C18 (125 
mm × 4.6 mm i.d., 5-μm particle diameter) manufactured by Thermo electron corporation 
(USA), coupled with a symmetry C18-Sentry guard column (20 mm). All solutions were 
degassed by ultrasonication (Technal, Brazil) and filtered through a 0.45-μm Millex filter 
(Millipore, waters).
A Shimadzu UV/VIS spectrophotometer, Model 1800 (Japan), was used for measuring 
the absorbance and recording normal and derivative spectra.
Chromatographic conditions
The mobile phase consisted of acetonitrile and 0.1 % diethyl amine (50:50, V/V, pH = 
4.5). The mobile phase was freshly prepared, then filtered and degassed. all separations 
were performed isocratically at a flow rate of 1 mL min–1. Column temperature was main-
tained at 25 ± 2 °C. The injection volume was 10 μL, and the detection wavelength was set 
at 240 nm.
Measurement of derivative spectra
Standard solutions of PS and FF were appropriately diluted with methanol to obtain 
solutions containing 10 mg mL–1 of PS and FF. These solutions were scanned in the region 
200–350 nm against methanol as blank. The zero-order spectra of PS and FF were treated to 
obtain the corresponding second-order derivative spectra using Δλ = 4 nm and scaling fac-
tor 16. Independent recordings of the spectra were carried out in triplicate. Distances h1 and 
h2 for PS and FF at 237.6 and 295.1 nm, respectively, were recorded in the derivative spectra 
(see below), and the concentration of each compound was calculated from the pre-con-
structed calibration graph.
Standard solutions
HPLC. – Stock solutions of pravastatin and fenofibrate were prepared by dissolving 
an appropriate amount of each compound in methanol to yield concentrations of 1.0 and 
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4.0 mg mL–1, resp. working standard solutions were prepared by dilution with methanol 
to give 100 and 400 μg mL–1 of PS and FF, respectively. The standard solution of darifenacin 
as internal standard (IS) (1.0 mg mL–1) was also prepared in methanol. The concentration 
of IS was maintained at 100 μg mL–1 in each combined solution of PS and FF used for quan-
titative studies. Stock solutions of 1 and 4 mg mL–1 were stable for at least one month when 
stored in refrigerator (4 °C) with no evidence of degradation in the chromatograms during 
that period.
Spectrophotometry. – Stock solutions of pravastatin and fenofibrate were prepared by 
accurate weighing of each and dissolving in methanol. The concentration of 200 μg mL–1 
was prepared in methanol after dilution. For simultaneous quantitative studies of both the 
drugs, a series of standard solutions containing both drugs were prepared by appropriate 
dilution of a mixture of stock solutions.
Samples
Twenty capsules (Pravafenix® capsule, Laboratoires SMB s.a., Belgium) (each capsule 
containing 40 PS plus 160 mg of FF) were emptied, the contents were ground and mixed 
well to a fine powder. an accurately weighed portion of the powder equivalent to 40 and 
160 mg of PS and FF, resp., was placed into a 100-mL volumetric flask. about 30 mL of 
methanol was added to that flask and sonicated in an ultrasonic bath for 5 min. This solu-
tion was then diluted to the mark with methanol and mixed. It was then filtered through 
a 0.22 μm nylon filter and the filtrate was collected after discarding the first few milliliters. 
different sample solutions of required concentrations were prepared using the filtrate.
For laboratory prepared sample 4.0 mg of PS and 16.0 mg of FF were added to the 
tablet powder (containing Mg-stearate, calcium hydrogenphosphate, silicon dioxide, starch 
and cellulose), finely powered, and transferred into a 100-mL calibrated flask, and then 40 
mL of distilled water was added. The contents of the flask were swirled and sonicated for 
15 minutes. The contents were completed to the mark with water, filtered, and the first por-
tion of the filtrate was rejected. Part of the remaining filtrate was diluted quantitatively with 
methanol to obtain the required concentrations for spectrophotometry and HPLC analysis.
Method validation
The proposed methods were fully validated in terms of linearity, sensitivity, selecti-
vity, accuracy and precision according to the criteria set by the International Conference on 
Harmonization (ICH) (20) and Food and drug administration (Fda) guidelines (21).
Linearity and sensitivity. – Under the specified optimum conditions, the calibration 
curves for PS and FF were constructed by analyzing a series of concentrations of the stan-
dard solutions of the drugs. Assays were performed according to the established general 
recommended procedures. Regression equations were derived using the least-squares 
method.
Accuracy and precision. – Accuracy of the second-derivative method for simultaneous 
determination of pravastatin and fenofibrate was checked at independently prepared con-
centration levels of 5, 10 and 15 μg mL–1 (n = 3). Precision of the assays was determined by 
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replicate analysis of five sample solutions of the working standards at three concentration 
levels on the same day and on three different days for each compound. Intra-day precision 
was expressed through the relative standard deviation of five replicate assays of sample at 
three concentration levels. Inter-day precision was determined by analyzing the same set 
of samples on five different days.
On the other hand, accuracy of the proposed HPLC method for simultaneous deter-
mination of pravastatin and fenofibrate was checked at independently prepared concen-
tration levels of 7.5, 12.5, 30.0 and 45.0 μg mL–1 (n = 3). Precision of the assay was deter-
mined by replicate analysis of four sample solutions of the working standards at the same 
day and on three different days. accuracy and precision of the method were determined 
for PS and Fe according to the Fda guidance for bioanalytical method validation (21). In-
tra- and inter-day precision was expressed through the relative standard deviation.
Specificity. – Before analyzing the investigated drugs in their pharmaceutical dosage 
forms, interference liabilities were performed to explore the effect of common excipients 
that might be added during formulations. Samples were prepared by mixing a known 
amount of the drug with various amount of common excipients: starch, sucrose, lactose, 
glucose, magnesium stearate, gum acacia and talc. Analysis of these laboratory-prepared 
samples was performed using the general recommended procedure and recovery values 
were determined.
Robustness and ruggedness. – In order to measure the extent of the method robustness, 
most critical parameters were varied while keeping the other parameters unchanged and, 
in parallel, the chromatographic profile was observed and recorded. Chromatographic and 
spectrophotometric parameters were varied within a range of 1–10 % of the optimum re-
commended conditions. The studied parameters were: the composition of the mobile 
phase, pH, flow rate and column temperature. ruggedness of the HPLC and spectropho-
tometric methods was evaluated by carrying out the analysis using two different analysts 
and different instruments on different days.
Limit of detection and limit of quantification. – The limit of detection (LOD) and the limit 




Absorption spectra. – The zero-order absorption spectra of pravastatin and fenofibrate 
alone as well as a mixture of the two compounds in methanol are shown in Fig. 2a. The 
wavelengths of maximum absorbance were found to be 237.6 and 295.1 nm for PS and FF, 
respectively. at the same time, the spectra of PS and FF in the mixture displayed over-
lapping in the region of 200–300 nm. This makes the determination of pravastatin in the 
presence of fenofibrate by conventional UV spectrophotometry difficult, but the determi-
nation of fenofibrate might be possible without interference from pravastatin in the region 
300 to 350 nm.
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The derivative spectrophotometry technique was, however, chosen for the determina-
tion of both drugs since it could remove broadband contributions from excipients and 
might also overcome the interference from peak overlapping. derivative spectra of differ-
ent orders were studied for both pravastatin and fenofibrate individually and simultane-
ously. The experiments showed that the second-derivative spectra of pravastatin and feno-
fibrate were simple and gave results with suitable precision at the Dl value of 4 nm. In the 
second-derivative spectra, the signals at 237.6 nm (zero-crossing point of fenofibrate) are 
proportional to the pravastatin concentration and the signals at 295.1 nm (pravastatin reads 
zero) are proportional to the fenofibrate concentration (Fig. 2b). The tangent method was 
used for the measurement of peak amplitude at 295.1 nm (of fenofibrate).
Two sets of solutions were recorded. The first set contained an increasing concentra-
tion of PS (5, 10, 15 and 20 μg mL–1) and a fixed concentration of FF (10 μg mL–1) (Fig. 2c) 
and the other contained an increasing concentration of FF (3, 5, 10, 15 and 20 μg mL–1) and 
Fig. 2. a) zero-order absorption spectra of 10 μg mL–1 of PS (----), 10 μg mL–1 of FF (……) and a mixture 
of 10 μg mL–1 of each PS and FF (—–). b) Second-order derivative absorption spectra of 10 μg mL–1 PS 
(……), FF (-------) and mixture of 10 μg mL–1 each PS and FF (—–). c) Second-derivative spectra of set 
of solutions containing 10 μg mL–1 of FF and different concentrations of PS (5, 10, 15 and 20 μg mL–1). 
d) Second-derivative spectra of the set of solutions containing 10 μg mL–1 of PS and different concen-
trations of FF (3, 5, 10, 15 and 20 μg mL–1).
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a fixed concentration of PS (10 μg mL–1) (Fig. 2d). The second-derivative spectra of the first 
set of solutions were found to exhibit two isodifferential points at 237.6 and 295.1 nm. The 
change in absorbance d2A with changing wavelength is zero for one component, while 
the other can be measured at that point without interference of the other. The amplitude 
for the trough at 237.6 nm (zero crossing point of FF) was found to be proportional to the 
concentration of PS. Thus, at 237.6 nm (isodifferential point d2A/wavelength), PS was 
determined selectively; at 295.1 nm (isodifferential point d2A/wavelength) FF was selec-
tively measured. Calibration graphs were prepared by plotting the absorbance at 295.1 in 
the second-order spectra, against the concentration of PS and FF in their binary solutions, 
and comparing the values obtained with the pre-constructed calibration graphs for PS 
and FF.
Method validation. – In all cases, Beer's plot (n = 3 number of repetitions of each point) 
was linear with a very small intercept and good correlation coefficient in the concentration 
range of 5–20 and 3–20 μg mL–1 for PS and FF, with the respective correlation coefficients 
of 0.998 and 0.997 (Table I), indicating good linearity in both cases.
The mean recovery data for each level (at 95 % confidence limit) was between 97.6–
100.4 and 98.2–101.4 % for FF and PS, respectively, for intra-day testing. Moreover, inter-
day testing showed the average recovery for FF and PS of 96.2–99.9 and 98.9–99.6 %, respec-
tively. The assays gave satisfactory results with the RSD value in the range 1.0–1.9 %. The 
results are reported in Table II.




Linearity range (μg mL–1) 5–20 3–20
wavelength (nm) 237.6 295.1
LOQ (μg mL–1) 5.0 3.0
LOD (μg mL–1) 1.5 1.0
Slope ± RSD (%) 0.0032 ± 1.2 0.00341 ± 2.9
Intercept ± RSD (%) 0.0003 ± 1.5 –0.01 ± 2.0
Molar absorptivity (L mol–1 cm–1) 0.9 × 104 0.1 × 105
Correlation coefficient (R) 0.998 0.997
HPLC
Linearity range (μg mL–1) 5–50 20–200
LOQ (μg mL–1) 5.0 20.0
LOD (μg mL–1) 1.5 6.5
Slope ± RSD (%) 0.0548 ± 5.1 0.022 ± 5.0
Intercept ± RSD (%) –0.0828 ± 8.6 –0.0699 ± 8.6
Correlation coefficient (R) 0.999 0.998
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The results indicate that there was no interference from the excipients used; recovery 
values were 97.5 % for FF and PS with the rSd value of 0.8 and 0.6 %, respectively. This 
indicates the absence of interference liabilities from the excipients.
The results obtained from lab-to-lab (two different laboratories) and day-to-day (dif-
ferent elapsed times) were found to be reproducible. The average recoveries were between 
97.6–100.4 and 98.2–101.4 % for FF and PS, respectively. The average recovery value was 
higher than 97.0 %.
HPLC
Method development. – Various mobile phases and stationary phases were tested in an 
attempt to obtain the best separation and resolution among PS, FF and internal standard. 
different compositions of the mobile phase were studied in order to shorten retention 
times of the analyte and to improve peak symmetry; best results were obtained using ace-
tonitrile/0.1 % diethylamine (50:50, V/V) as a mobile phase. The pH of the mobile phase was 
adjusted with 20 % o-phosphoric acid to pH 4.5.
System suitability. – Capacity factor (k'), asymmetry of the peaks, number of theoretical 
plates, the height equivalent to the theoretical plate, tailing factor and resolution between 
two consecutive peaks were evaluated. Results of system suitability testing are presented 
in Table III. The peaks of PS, FF and IS were well resolved, with retention times of 2.15, 5.79 
and 14.0 min, respectively. Analysis was achieved within 18 min for a total chromatogra-
phy run. A good resolution was obtained between two consecutive peaks in the developed 
method. The capacity factor, separation factor and tailing factor were 46.93 and 158.73, 1.25 
and 3.38 and 1.14 and 1.05, respectively, for PS and FF.
Method validation. – The results indicated that there was no interference from the ex-
cipients used; recovery values were 97.0–98.3 % with the RSD value of 0.3–0.6 %. This in-
Table II. Accuracy and precision of the proposed spectrophotometric method for determination of a binary 
mixture (intra-day and inter-day)
Added (μg mL–1) Recovery (%)a RSD (%)a
Intra-day
FF PS FF PS FF PS
  5   5 100.4 98.2 1.6 1.7
10 10   99.1 99.1 1.5 1.2
15 15   97.6 101.40 1.0 1.0
Inter-day
  5   5   99.9 99.6 1.8 1.9
10 10   98.8 98.8 1.5 1.5
15 15   98.3 99.4 1.4 1.2
a Average of three replicates.
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dicates the absence of interference liabilities from these excipients. Figs. 3a and b show 
chromatograms of placebo spiked with 100 μg mL–1 of internal standard. Fig. 3c shows the 
chromatogram of the drug formulation with 4 and 20 μg mL–1 of PS and FF, respectively, 
and 100 μg mL–1 IS. no endogenous peak from placebo was found to interfere with the PS, 
Fig. 3. HPLC chromatograms of: a) blank sample, b) blank sample spiked with 100 μg mL–1 of darif-
enacin (IS) and c) Pravafenix capsule sample (containing 4 μg mL–1 of pravastatin and 20 μg mL–1 of 
fenofibrate) and 100 μg mL–1 of darifenacin (IS).
Table III. Chromatographic parameters for PS and FF by the proposed HPLC method
Parameter PS FF
Retention time (min) 2.15 05.79
Capacity factor (k’) 46.930 158.730
Separation factor (a) 1.25 03.38
Resolution factor (Rs) 1.50 14.95
number of theoretical plates (N) 1723.60000 4053.0100
HETP (μm) 72.52 0 30.84
Tailing factor (asymmetry factor) 1.14 01.05
k’ – the average retention factor for the two bands.
The column plate number was determined using the formula: N = 5.54 (tR/wh)2, where wh is the bandwidth at 50 % 
of peak height.
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Table IV. Intra-day and inter-day reproducibility of a model sample of pravastatin and 




Accuracy (%) RSD (%) Accuracy (%) RSD(%)
PS
  7.5 102.6 0.6 97.3 0.7
12.5   97.6 0.3 97.6 0.3
30.0 101.6 0.2 100.00 1.6
45.0 102.0 0.7 101.70 1.1
FF
30.0   97.3 0.7 97.0 1.1
50.0   97.4 0.4 97.2 0.7
120.00   98.3 0.6 98.1 0.7
180.00   98.9 0.8 98.3 0.5




Flow rate (mL min–1)
  0.9 101.1 98.5
  1.0 100.9 99.0
  1.1   96.3 97.3
Injection volume (μL)
  8.0   97.6 98.0
10.0   99.8 98.5
15.0   98.1 96.7
pH
  4.0 100.2 100.00
  4.5   96.2 97.5
  4.7   98.0 98.0
Daya
  1.0 100.1 99.0
  2.0 100.3 98.0
  3.0   99.7 98.5
Temperature (°C)
25.0   99.3 98.5
30.0   99.1 97.5
35.0   98.6 99.0
–80.00   97.5 98.0
Analyst
  1.0   98.8 98.0
  2.0   98.1 98.7
a Solution was stored at room temperature.
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FF or IS elution. The peaks were in good shape and completely separated one from the 
other.
Linear relationship was demonstrated between peak area ratios of both PS and FF 
over IS and drug concentrations over a range of 5–50 and 20–200 μg mL–1, respectively, 
with the correlation coefficient (R) of 0.999 and 0.998. Table I summarizes the precision of 
calibration curve parameters. The LOQ of PS and FF were estimated as 5 and 20 μg mL–1, 
at which the accuracy was between 97.0–98.5 % and precision was less than 2 %. Limit of 
detection (LOD) was 1.5 and 6.5 μg mL–1 resp. (21).
Accuracy and precision. – The RSD values of intra-day (0.6–0.7 and 0.4–0.8 %) and inter-
day (0.3–1.1 and 0.5–1.1 %) studies for PS and FF showed that the precision of the method 
was satisfactory (Table IV). Accuracy of the analytical method used was 97.0–98.9 % for 
intra- and inter-day, respectively.
Model samples of PS and FF were used for stability experiments. Stability was as-
sessed under a variety of conditions. no evidence of degradation was noticed during 
sample processing and storing for at least one month, in a freezer at –80 °C. no effects of 
short term stability of frozen samples kept at room temperature for 6 h on quantification 
of PS and FF were observed. These studies suggest that the samples containing both drugs 
can be handled under normal laboratory conditions without any significant loss of drugs 
(Table V).
results obtained using two different analysts and different instruments were found 
to be reproducible. An error not greater than 4 % was observed (Table V).
Application to dosage forms
The two proposed methods were applied to the determination of PS and FF in their 
commercial dosage form and in a laboratory prepared formulation (see Experimental). 
Satisfactory results were obtained and are in good agreement with the reported methods 
(4, 12) (Table VI). There was no significant difference between the two proposed methods 
and between either of them and the reference methods with regard to accuracy and preci-
sion.
ConCLUSIonS
The present study investigates for the first time the development of two methods 
(HPLC and second-derivative spectrophotometry) for the simultaneous determination of 
PS and FF in pharmaceutical formulations. The methods are rapid, accurate and reliable, 
without interference from common excipients. due to their simplicity and sufficient sensi-
tivity, the proposed methods can be used in quality control laboratories. The advantage of 
the derivative spectrophotometric method over the HPLC method is its low cost. On the 
other hand, the advantage of HPLC over the derivative spectrophotometry is its selectivity 
and applicability to the analysis of drugs in a variety of matrices.
Acknowledgements. – The authors extend their appreciation to the deanship of Scientific research 
at King Saud University for funding the work through the research group project no. rGP-VPP-037.
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